To assess the cost-effectiveness of an early treatment of upper gastro-intestinal haemorrages in cirrhotic patients.
Utilization data linked to the results of a double-blind, placebo-controlled trial demonstrating the efficacy of the terlipressin-glycerin trinitrate combination (TER-GTN) in the reduction of mortality at day 42 for haemorragic patients due to rupture of oesophageal varices.
Hôpital Jean Verdier, Bondy, Assistance Publique-Hôpitaux de Paris, France.
Eighty-four patients included over 2 years by emergency services and hospitalized in an intensive care unit (ICU) for haemorrage, 41 in the « treated » group and 43 in the « placebo » group.
Mortality at day 42, cost per death avoided.
The mortality rate in the placebo group was 46.5% versus 27.5% in the treated group.
The mean length of stay was 5 days longer in the treatment group.
The excess cost per death avoided was 25,849 FF.
Of this extra cost 27% was due to treatment and 24% was due to increased length of stay.
The excess cost per case treated was FF 5,097,10% of the total cost per stay for rupture of oesophageal varices (ROV).
Our results are of the same magnitude as those published by Mac Cormick et al. in the United Kingdom for similar treatment.
The extra cost appears to be moderate, and much lower than monoclonal antibody therapy for sepsis.
The impact on the study hospital budget did not exceed 1.7 10-4.
Mots-clés Pascal : Analyse coût efficacité, Période préhospitalière, Hémorragie, Gastrointestinal, Aigu, Cirrhose, Terlipressine, Vasoconstricteur, Varice, Oesophage, Rupture tissu, Complication, Association médicamenteuse, Traitement, Chimiothérapie, Homme, Nitroglycérine, Economie santé, Appareil digestif pathologie, Estomac pathologie, Intestin pathologie, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Foie pathologie, Hormone neurohypophysaire, Vasopressine, Oesophage pathologie, Circulation portale pathologie, Veine pathologie
Mots-clés Pascal anglais : Cost efficiency analysis, Prehospital period, Hemorrhage, Gastrointestinal, Acute, Cirrhosis, Terlipressin, Vasoconstrictor agent, Varix, Esophagus, Tissue rupture, Complication, Drug combination, Treatment, Chemotherapy, Human, Nitroglycerin, Health economy, Digestive diseases, Gastric disease, Intestinal disease, Cardiovascular disease, Vascular disease, Hepatic disease, Neurohypophyseal hormone, Vasopressin, Esophageal disease, Portal circulation disease, Venous disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0217523
Code Inist : 002B02H. Création : 16/11/1999.